# BESPONSA Injection 1 mg Special Investigation

> **NCT05923112** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 421 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05923112
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923112, "BESPONSA Injection 1 mg Special Investigation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05923112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*